Advancing QbD in the EU - EU authorities are stepping up their efforts to incorporate QbD principles. - BioPharm International

ADVERTISEMENT

Advancing QbD in the EU
EU authorities are stepping up their efforts to incorporate QbD principles.


BioPharm International
Volume 26, Issue 4, pp. 14-15

The European Commission's latest revision of its GMP guide, effective from Jan. 31, 2012, shows the degree to which it is responding to calls for ICH guidelines to be given greater prominence in EU rules on quality in pharmaceuticals. Chapter 1 of the guide has been changed to align it with the concepts and terminology of the ICH Q10 guideline on pharmaceutical quality systems. It makes clear that this new chapter will also apply to two existing pieces of EU legislation on the principles and guidelines of GMP—one, for medicines for human use, and other, for veterinary applications. References in the legislation to "an effective quality-assurance system" that manufacturers must establish and implement will now be taken to mean the ICH pharmaceutical quality system. "For the purposes of this chapter, these terms can be considered to be interchangeable," states the revised guide.

Chapter 7 of the guide on outsourced activities has also been revised to take into account the ICH Q10 guideline. The biggest change in the GMP guide is a massive extension of Annex 2 on the manufacture of biological active substances, which has been extended from five to 32 pages and from 43 sub-items to 70.

"The enlargement has been necessitated by the introduction of new manufacturing technologies and the increased breadth of biological medicines into areas like gene and cell therapy," says the Commission. It is also because of the incorporation of components of the ICH guideline on QRM. "These biological principles may display inherent variability," the new annex states. "As a result, QRM principles are particularly important for this class of materials." The annex includes a new section on operating principles emphasizing the need for control strategies based on QRM principles to cover various key features of production processes.

The GMP guide may have to be further updated to highlight the importance of certain aspects of ICH guidelines because of what EMA describes as "public health crises" due to disruption to drug supplies caused by manufacturing problems. In a discussion paper issued in late 2012, the agency pinpointed the need for tighter controls on outsourced manufacturing to ensure that it is GMP compliant. EMA also thought that details of the "pre-planned inclusion of failsafe manufacturing site capacity" should possibly be included in marketing authorizations. In the longer term, the agency is considering making some QbD elements mandatory rather than optional by requiring submissions by all marketing authorization holders of risk analyses of their manufacturing processes to identify weaknesses.

REDUCING MEDICINE SHORTAGES

EMA is also looking to collaborate with other licensing agencies outside Europe on ways to reduce drug scarcities, including the sharing of information about product-supply issues. EMA is already involved in a joint program with FDA on the parallel assessment of marketing authorization and new drug applications, which include QbD approaches.

One key objective of the three-year program, due to end in March next year, is to ensure consistency between the EU and the US in the implementation of ICH Q8, Q9, and Q10 guidelines. Assessments of applications are being done in parallel by the two agencies after which the review teams will discuss lessons to be learned and identify knowledge gaps. The pilot scheme should increase the momentum behind the uptake of QbD principles in Europe among both regulators and pharmaceutical manufacturers as well as lead to a more uniform policy between the EU and the US in the use of QbD to tackle issues like drug shortages due to production disruptions.

Sean Milmo is a freelance writer based in Essex, UK,


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Harnessing the Power of Modified T Cells to Treat Cancer
October 17, 2014
Lilly to Close Manufacturing Facility in Puerto Rico
October 17, 2014
BioReliance Introduces New Predictive Assays
October 17, 2014
Industry Stakeholders Tackle the Use of Biological Qualifiers at WHO Naming Session
October 16, 2014
Pfizer Ireland Plant Receives ISPE Award
October 16, 2014
Author Guidelines
Source: BioPharm International,
Click here